<DOC>
	<DOCNO>NCT02083185</DOCNO>
	<brief_summary>This 3-arm , randomize , open-label , parallel group study TAK-385 , together leuprorelin observational cohort , patient prostate cancer require first-line androgen deprivation therapy ( ADT ) .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Safety Efficacy TAK-385 , Together With Leuprorelin Observational Cohort , Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Each patient must meet follow inclusion criterion enrol study : 1 . Male patient 18 year old 2 . Histologically cytologically confirm diagnosis prostate adenocarcinoma 3 . Candidate androgen deprivation therapy ( ADT ) management hormonesensitive prostate cancer 1 follow clinical disease state : 1 ) advance localized disease suitable primary therapy , 2 ) evidence prostatespecific antigen ( PSA ) biochemical clinical relapse follow primary surgery radiation therapy curative intent , 3 ) newly diagnose metastatic disease asymptomatic threatening vital organ 4 . Appropriate serum testosterone serum PSA concentration screen specify protocol 5 . A body mass index ( BMI ) â‰¥ 18.0 screen and/or baseline 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 screen and/or baseline . 7 . Male patient , even surgically sterilize , agree practice effective barrier contraception agree practice true abstinence . 8 . Voluntary write consent must give performance studyrelated procedure part standard medical care , understand consent may withdraw patient time without prejudice future medical care 9 . Suitable venous access studyrequired blood sampling , include PK PD Sampling Exclusion Criteria Patients meeting follow exclusion criterion enrol study : 1 . In patient advanced , localized M0N1 M1 disease , presence clinically significant symptom threat vital organ require immediate GnRH/CAB therapy , chemotherapy , radiotherapy 2 . Previously receive ADT 8 month total duration ( ADT receive 8 month less , ADT must complete least 2 year prior screen ) 3 . Visceral metastasis ( liver lung ) 4 . Features patient 's medical condition may make ADT unnecessary indicate . 5 . Scheduled additional surgical ( salvage ) radiation therapy within 6 month baseline evaluation 6 . History surgical castration 7 . Diagnosis treatment another malignancy within 2 year first dose study drug , previously diagnose another malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection 8 . Abnormal screen and/or baseline laboratory value specify protocol 9 . History significant cardiac condition within 6 month receive first dose study drug 10 . ECG abnormality specify protocol 11 . Congenital long QT syndrome 12 . Current use Class IA ( eg , quinidine , procainamide ) Class III ( eg , amiodarone , sotalol ) antiarrhythmic medication 13 . Uncontrolled hypertension despite appropriate medical therapy . Patients may rescreened referral management hypertension 14 . Known , previously diagnose human immunodeficiency virus ( HIV ) infection , active chronic hepatitis B C , lifethreatening illness unrelated prostate cancer , serious medical psychiatric illness could , investigator 's opinion , potentially interfere participation study . Specific screen chronic viral illness discretion site and/or local institutional review board ( IRB ) 15 . Treatment investigational product within 3 month first dose study drug 16 . A primary family member ( spouse , parent , child , sibling patient ) involve conduct study study site employee 17 . Known gastrointestinal ( GI ) disease GI procedure could interfere oral absorption tolerance TAK385 , include difficulty swallow tablet 18 . Use medication , food product list excluded medication dietary product table within 2 week first dose study drug . Patient must history amiodarone use 6 month first dose TAK385 19 . Admission evidence alcohol drug abuse use illicit drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>